Bellerophon Provides Business Update and Reports Second Quarter 2019 Financial Results
August 08, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business...
Bellerophon Completes Enrollment in Cohort 2 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
August 01, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it has...
Bellerophon to Present at the JMP Securities Life Sciences Conference
June 13, 2019 08:00 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., June 13, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today that Fabian...
Bellerophon to Host Key Opinion Leader Meeting Focused on Pulmonary Hypertension Associated with Interstitial Lung Disease
May 22, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 22, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will...
Bellerophon Presents Additional Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference
May 21, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 21, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, presented additional data...
Bellerophon to Present Additional Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference
May 13, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
Results to be Presented in Late-Breaking Abstract as an Oral Presentation Company will Also Present a Corporate Overview and Update on its PH-ILD Program at Respiratory Innovation Summit WARREN,...
Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results
May 09, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., May 09, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business...
Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
April 08, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
FDA Agrees to Primary Endpoint of Change in Moderate to Vigorous Physical Activity from Baseline to Week 16, Measured by Actigraphy FDA Also Agrees on Modification of Ongoing Phase 2b Study into a...
Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
March 14, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
WARREN, N.J., March 14, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business...
Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients
January 28, 2019 08:30 ET
|
Bellerophon Therapeutics, Inc.
Actigraphy is Being Utilized to Evaluate Multiple Clinically Meaningful Activity Parameters in the Ongoing INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with...